FimmCyte
We a novel first in-class treatment for Endometriosis based on the immune system.
FimmCyte has raised €1.2M across 2 funding rounds from 2 investors, most recently a Debt round in Feb 2024. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€1.2M
€1,201,488
Funding rounds
2
Investors
2
distinct backers
Active since
2022-07
latest 2024-02
Funding by year
EUR raised per yearFimmCyte — funding by year — interactive chart.
Data table
| FimmCyte — funding by year | |
|---|---|
| 2022 | €153k |
| 2024 | €1.0M |
Signals
High confidenceRaise-next likelihood9
base rate 45% for Debt
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood6
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-02-29 | Debt | €1.0M | UZH Life Sciences Fund (LSF) | View deal → |
| 2022-07-13 | Other | €153k | Venture Kick | View deal → |
Investors
2Related news
- FimmCyte obtains CHF 150’000 to tackle Endometriosisstartupticker.ch · 2022-07
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData